
Rehospitalization is a common endpoint in clinical trials of structural heart interventions, but whether rehospitalization is clinically and prognostically relevant in these patients is uncertain. This study aimed to evaluate the risk of rehospitalization events after aortic valve replacement (AVR) and their association with mortality and health status. The study population included patients who underwent transcatheter or surgical AVR in the PARTNER I‚, II‚ and III trials (Placement of Aortic Transcatheter Valves). Heart failure hospitalization and rehospitalization after AVR are associated with increased risk of mortality and worse 1-year health status. These findings confirm the clinical and prognostic relevance of rehospitalization endpoints for trials of AVR.
Like
Save
Share